Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum

SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ — Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional…

About the Author

has written 39120 stories on this site.

Copyright © 2010 Business and Corporate News.